HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor
Status:
Not yet recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
A single center, open, single arm dose escalation phase I study to evaluate the safety,
tolerability, and efficacy of HRYZ-T101 TCR-T cell for HPV18 positive advanced solid tumor.
The study will investigate DLT of HRYZ-T101 TCR-T cell injection.